Automate Your Wheel Strategy on QURE
With Tiblio's Option Bot, you can configure your own wheel strategy including QURE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol QURE
- Rev/Share 0.2692
- Book/Share 3.9091
- PB 6.2585
- Debt/Equity 0.2892
- CurrentRatio 7.117
- ROIC -0.2274
- MktCap 1507136967.0
- FreeCF/Share -2.6252
- PFCF -9.8109
- PE -6.0881
- Debt/Assets 0.0745
- DivYield 0
- ROE -3.7373
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | QURE | Wolfe Research | -- | Peer Perform | -- | -- | Feb. 24, 2026 |
| Initiation | QURE | Barclays | -- | Equal Weight | -- | $31 | Jan. 28, 2026 |
| Downgrade | QURE | William Blair | Outperform | Market Perform | -- | -- | Nov. 4, 2025 |
| Upgrade | QURE | Mizuho | Neutral | Outperform | -- | $30 | Aug. 14, 2025 |
| Resumed | QURE | Chardan Capital Markets | -- | Buy | -- | $38 | April 1, 2025 |
| Upgrade | QURE | Raymond James | Outperform | Strong Buy | -- | -- | Dec. 10, 2024 |
| Resumed | QURE | Raymond James | -- | Outperform | -- | $20 | Oct. 10, 2024 |
News
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
~ AMT-130 granted Breakthrough Therapy designation by FDA ~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no treatment-related serious adverse events ~ ~ Held Type B FDA meetings in the first and second quarters of 2025 to advance BLA preparations for AMT-130; regulatory update expected in the second quarter of 2025 ~ ~ AMT-260 clinical data from first patient to be presented at Epilepsy Therapies & Diagnostics Development Symposium on May 29, 2025 ~ ~ Cash, cash equivalents and current investment securities of approximately $409.0 million as of …
Read More
uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Positive
uniQure's lead program for Huntington's Disease is planning to file an application via the accelerated approval pathway. On Monday, May 5th, PTC Therapeutics announced positive results from their phase 2 Huntington's Disease trial. I compare the data from these two treatments and share my thoughts here.
Read More
uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive
uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130
Published: April 21, 2025 by: Seeking Alpha
Sentiment: Positive
uniQure's AMT-130 gene therapy for Huntington's Disease shows promising trial data, leading to significant stock price increases and potential for FDA accelerated approval. QURE's stock has seen volatility but has near-term catalysts like BLA submission and 36-month trial data, suggesting potential for immediate further gains. Despite competition from PTC518, AMT-130's effectiveness and one-time treatment advantage could drive substantial revenue and stock price growth.
Read More
uniQure N.V.: A Potential Huntington's Play
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Positive
uniQure's stock surged in December due to positive data around its Huntington's disease candidate AMT-130, clearing the way for potential accelerated FDA approval without another trial. The company's gene therapy Hemgenix, approved for hemophilia B, and three new clinical programs, including AMT-191, AMT-162, and AMT-260, bolster its pipeline. Cost-cutting measures and strategic financing have extended uniQure's operating runway through 2Q28, with significant analyst support and price targets up to $70 a share.
Read More
About uniQure N.V. (QURE)
- IPO Date 2014-02-05
- Website https://www.uniqure.com
- Industry Biotechnology
- CEO Matthew Craig Kapusta
- Employees 209